AU2016345063B2 - A method of treatment and agents useful for same - Google Patents

A method of treatment and agents useful for same Download PDF

Info

Publication number
AU2016345063B2
AU2016345063B2 AU2016345063A AU2016345063A AU2016345063B2 AU 2016345063 B2 AU2016345063 B2 AU 2016345063B2 AU 2016345063 A AU2016345063 A AU 2016345063A AU 2016345063 A AU2016345063 A AU 2016345063A AU 2016345063 B2 AU2016345063 B2 AU 2016345063B2
Authority
AU
Australia
Prior art keywords
val
ser
thr
glu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016345063A
Other languages
English (en)
Other versions
AU2016345063A2 (en
AU2016345063A1 (en
Inventor
Perry Bartlett
Andrew Boyd
Leanne COOPER
Mike GEROMETTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
QIMR Berghofer Medical Research Institute
Original Assignee
University of Queensland UQ
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904387A external-priority patent/AU2015904387A0/en
Application filed by University of Queensland UQ, Queensland Institute of Medical Research QIMR filed Critical University of Queensland UQ
Publication of AU2016345063A1 publication Critical patent/AU2016345063A1/en
Publication of AU2016345063A2 publication Critical patent/AU2016345063A2/en
Application granted granted Critical
Publication of AU2016345063B2 publication Critical patent/AU2016345063B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2016345063A 2015-10-27 2016-10-27 A method of treatment and agents useful for same Active AU2016345063B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015904387A AU2015904387A0 (en) 2015-10-27 A method of treatment and agents useful for same
AU2015904387 2015-10-27
PCT/AU2016/051010 WO2017070738A1 (en) 2015-10-27 2016-10-27 A method of treatment and agents useful for same

Publications (3)

Publication Number Publication Date
AU2016345063A1 AU2016345063A1 (en) 2018-05-17
AU2016345063A2 AU2016345063A2 (en) 2018-07-19
AU2016345063B2 true AU2016345063B2 (en) 2021-08-05

Family

ID=58629613

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016345063A Active AU2016345063B2 (en) 2015-10-27 2016-10-27 A method of treatment and agents useful for same

Country Status (7)

Country Link
US (1) US10617738B2 (enExample)
EP (1) EP3368551B1 (enExample)
JP (1) JP6877419B2 (enExample)
CN (1) CN108884135B (enExample)
AU (1) AU2016345063B2 (enExample)
ES (1) ES2959601T3 (enExample)
WO (1) WO2017070738A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110702916B (zh) * 2019-04-15 2022-06-21 四川大学华西医院 一种整合蛋白质组和糖蛋白组的定量分析方法
EP4308149A4 (en) * 2021-03-18 2025-02-26 Valery Krasnoperov Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
AU2022388189A1 (en) * 2021-11-11 2024-05-02 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
WO2023154948A1 (en) * 2022-02-14 2023-08-17 Vasgene Therapeutics Inc. Ephrin type-b receptor 4 (ephb4) agents and production thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024413A1 (en) * 1998-10-27 2000-05-04 The Walter And Eliza Hall Institute Of Medical Research A method of treatment
US20080003210A1 (en) * 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
US7892769B2 (en) * 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
US8137926B2 (en) * 2007-06-08 2012-03-20 Eisai R&D Management Co., Ltd. Kit for assaying EphA4 processing by gamma-secretase
US8865426B2 (en) * 2010-12-17 2014-10-21 Eisai R&D Management Co., Ltd. Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0425731B1 (de) 1989-11-03 1994-01-19 Siemens Aktiengesellschaft Controller-Bussystem für einen programmierbaren, flexiblen Digitalsignal-Multiplexer
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
DE69423522T2 (de) 1993-04-27 2000-09-21 Cytotherapeutics, Inc. Membran aus einem acrylnitrilpolymer
NZ269041A (en) 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5853717A (en) 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
CA2202747A1 (en) 1995-06-01 1996-12-05 Dennis Keen Warren Communication system to provide called party location and pre-call warning
IN181898B (enExample) 1995-06-07 1998-10-24 Cytotherapeutics Inc
WO1997012635A1 (en) 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
JP2007525203A (ja) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４
EP2260864A1 (en) * 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024413A1 (en) * 1998-10-27 2000-05-04 The Walter And Eliza Hall Institute Of Medical Research A method of treatment
US20080255044A1 (en) * 1998-10-27 2008-10-16 The Walter And Eliza Hall Institute Of Medical Research Method of treatment
US20080003210A1 (en) * 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
US8137926B2 (en) * 2007-06-08 2012-03-20 Eisai R&D Management Co., Ltd. Kit for assaying EphA4 processing by gamma-secretase
US7892769B2 (en) * 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
US8865426B2 (en) * 2010-12-17 2014-10-21 Eisai R&D Management Co., Ltd. Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOLDSHMIT et al., "EphA4 Blockers Promote Axonal Regeneration and Functional Recovery Following Spinal Cord Injury in Mice.", PLOS ONE, (2011), vol. 6, no. 9, e24636, pages 1 - 12 *

Also Published As

Publication number Publication date
US20180339020A1 (en) 2018-11-29
AU2016345063A2 (en) 2018-07-19
WO2017070738A1 (en) 2017-05-04
EP3368551A1 (en) 2018-09-05
EP3368551B1 (en) 2023-07-12
JP6877419B2 (ja) 2021-05-26
ES2959601T3 (es) 2024-02-27
US10617738B2 (en) 2020-04-14
CN108884135B (zh) 2024-03-26
CA3003294A1 (en) 2017-05-04
CN108884135A (zh) 2018-11-23
JP2019501112A (ja) 2019-01-17
AU2016345063A1 (en) 2018-05-17
EP3368551A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
US10287336B2 (en) Feline erythropoietin receptor agonists
EP3368551B1 (en) A modified epha4 polypeptide
EP1539964B1 (en) Collectin-complement activating protein chimeras
KR20070053732A (ko) 단백질 생산 시스템 및 생산 방법
JP2009062372A (ja) 高分子質量レクチンの生産
CA3003294C (en) Modified epha4 and uses thereof
JP6120133B2 (ja) 人工ポリクローナル免疫グロブリン組成物
JP2025036661A (ja) 抗体酵素の革新的製造技術
EP3366770A1 (en) Dna vaccine against amyloid-beta and tau
KR102485892B1 (ko) 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR102201154B1 (ko) 폴리글루타메이트-TAT-Cre 융합 단백질의 제조방법
JP4995399B2 (ja) 切断されたｂａｒｄ１タンパク質、並びにその診断上及び治療上の利用
CN116139278B (zh) 一种tim-3棕榈酰化修饰及靶向多肽在肿瘤免疫治疗中的应用
US20250250320A1 (en) Thrombopoietin receptor fragments and uses thereof
CN117642422A (zh) 用于降低抗体-脂肪酶结合的结构
WO2004106370A1 (en) M11l derived peptides and therapeutic use thereof
JP2026514409A (ja) ＩｄｅＳバリアントタンパク質及びそれを使用する方法
KR20240087579A (ko) 항-타우 항체 및 펩티드를 포함하는 융합체와 그의 용도
JPWO2009017255A1 (ja) 変異導入ＭｙＤ８８蛋白によるＴｏｌｌ様受容体／インターロイキン１８シグナルの特異的制御法
Vladimirova et al. State of protein B23/nucleophosmin in brain cells
HK1165461A (en) In tumours differentially expressed gene products and use of the same
HK1165468A (en) In tumours differentially expressed gene products and use of the same
HK1165478A (en) In tumours differentially expressed gene products and use of the same
HK1165476A (en) In tumours differentially expressed gene products and use of the same
HK1165479A (en) In tumours differentially expressed gene products and use of the same

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 JUN 2018

FGA Letters patent sealed or granted (standard patent)